Back to search
FDAFDA · Food and drugs·Recall number D-0035-2020

Natpara (parathyroid hormone) for Injection, 25 mcg/dose, 2 pack cartridges, Rx only, For subcutaneous use only, Manufactured for: Shire-NPS Pharmaceuticals, Inc., Lexington, MA NDC 68875-0202-02

Published October 2, 2019 · Recall initiated: September 12, 2019

Summary

FDA records drug Class I recall D-0035-2020, published October 2, 2019 and initiated September 12, 2019. Recalling firm: Shire Human Genetic Therapies, Inc.; Status: Terminated; Reported quantity: 1,556; Lot: 08569357, exp 4/30/2020; 07983652, 08544833, exp 6/30/2021. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Shire Human Genetic Therapies, Inc.
Distributor
Product was distributed throughout the United States.
Lot
08569357, exp 4/30/2020; 07983652, 08544833, exp 6/30/2021
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Natpara (parathyroid hormone) for Injection, 25 mcg/dose, 2 pack cartridges, Rx only, For subcutaneous use only, Manufactured for: Shire-NPS Pharmaceuticals, Inc., Lexington, MA NDC 68875-0202-02 recalled?

Yes. FDA published recall D-0035-2020 on October 2, 2019. Reported hazard: Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

What should I do if I have this product?

Voluntary: Firm initiated · Letter